Publications

ADT-1004: A First-in-Class, Orally Bioavailable Selective pan-RAS Inhibitor for 1 Pancreatic Ductal Adenocarcinoma

Download PDF
Resource: ADT-1004: A First-in-Class, Orally Bioavailable Selective pan-RAS Inhibitor for 1 Pancreatic Ductal Adenocarcinoma

.

Related Articles

Microfluidics-assisted multiplexed biomarker detection for in situ mapping of immune cells in tumor sections

Link
B cell-based therapy produces antibodies that inhibit glioblastoma growth

Link